AlphaCentric Advisors’s Spyre Therapeutics SYRE Stock Holding History

AlphaCentric Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$592K	Buy	6,670 +36	+0.5%	+$2.63K	0.5%	72
2026 Q1	$335K	Buy	+6,634	New	+$250K	0.33%	97
2021 Q4	–	Sell	-4,400	Closed	-$875K	–	269
2021 Q3	$875K	Buy	4,400 +700	+19%	+$122K	0.22%	39
2021 Q2	$644K	Buy	3,700 +2,860	+340%	+$520K	0.17%	48
2021 Q1	$166K	Buy	840 +680	+425%	+$130K	0.06%	108
2020 Q4	$31K	Buy	160 +40	+33%	+$8.29K	0.01%	195
2020 Q3	$21K	Buy	+120	New	+$22.2K	0.01%	146

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

AlphaCentric Advisors's SYRE Position: Q2 2026 in Review

AlphaCentric Advisors increased its Spyre Therapeutics (SYRE) stake by 0.54% in Q2 2026, buying an estimated $2.63K and bringing the position to 6,670 shares worth $592K. The position accounts for 0.5% of the portfolio, ranked #72.

AlphaCentric Advisors first reported a position in SYRE in Q3 2020 and has held it in 7 quarters since. The position peaked at $875K in Q3 2021. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

AlphaCentric Advisors held 6,670 shares of Spyre Therapeutics worth $592K as of Q2 2026.
AlphaCentric Advisors bought 36 Spyre Therapeutics shares in Q2 2026, an estimated $2.63K.
Spyre Therapeutics made up 0.5% of AlphaCentric Advisors's portfolio in Q2 2026, its #72 holding.
AlphaCentric Advisors first reported a position in Spyre Therapeutics in Q3 2020 and has held it in 7 quarters since.
AlphaCentric Advisors's Spyre Therapeutics position peaked at $875K in Q3 2021.
265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.